Cargando…

The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance

BACKGROUND: Nowadays, the incidence rate of advanced and metastatic prostate cancer at the first time of diagnosis grows higher in China yearly. At present, androgen deprivation therapy (ADT) is the primary treatment of advanced prostate cancer. However, after several years of ADT, most patients wil...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ao, Gao, Yi, Wang, Qi, Lin, Wenhao, Ma, Zhiyang, Yang, Xiaoqun, Chen, Lu, Xu, Danfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510184/
https://www.ncbi.nlm.nih.gov/pubmed/37726835
http://dx.doi.org/10.1186/s12967-023-04320-2
_version_ 1785107911699070976
author Liu, Ao
Gao, Yi
Wang, Qi
Lin, Wenhao
Ma, Zhiyang
Yang, Xiaoqun
Chen, Lu
Xu, Danfeng
author_facet Liu, Ao
Gao, Yi
Wang, Qi
Lin, Wenhao
Ma, Zhiyang
Yang, Xiaoqun
Chen, Lu
Xu, Danfeng
author_sort Liu, Ao
collection PubMed
description BACKGROUND: Nowadays, the incidence rate of advanced and metastatic prostate cancer at the first time of diagnosis grows higher in China yearly. At present, androgen deprivation therapy (ADT) is the primary treatment of advanced prostate cancer. However, after several years of ADT, most patients will ultimately progress to castration-resistant prostate cancer (CRPC). Previous studies mainly focus on Caucasian and very few on East Asian patients. METHODS: In this study, the pre- and post-ADT tumor samples were collected from five Chinese patients with advanced prostate cancer. The whole-exome sequencing, tumor heterogeneity, and clonal evolution pattern were analyzed. RESULTS: The results showed that the gene mutation pattern and heterogeneity changed significantly after androgen deprivation therapy. Tumor Mutational Burden (TMB) and Copy Number Alteration (CNA) were substantially reduced in the post-treatment group, but the Mutant-allele tumor heterogeneity (MATH), Socio-Demographic Index (SDI), Intratumor heterogeneity (ITH), and weighted Genome Instability Index (wGII) had no significant difference. According to the clone types and characteristics, the presence of main clones in five pre-and post-treatment samples, the clonal evolution pattern can be further classified into two sub-groups (the Homogeneous origin clonal model or the Heterogeneous origin clonal model). The Progression-free survival (PFS) of the patients with the “Homogeneous origin clonal model” was shorter than the “Heterogeneous origin clonal model”. The longer PFS might relate to MUC7 and MUC5B mutations repaired. ZNF91 mutation might be responsible for resistance to ADT resistance. CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04320-2.
format Online
Article
Text
id pubmed-10510184
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105101842023-09-21 The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance Liu, Ao Gao, Yi Wang, Qi Lin, Wenhao Ma, Zhiyang Yang, Xiaoqun Chen, Lu Xu, Danfeng J Transl Med Research BACKGROUND: Nowadays, the incidence rate of advanced and metastatic prostate cancer at the first time of diagnosis grows higher in China yearly. At present, androgen deprivation therapy (ADT) is the primary treatment of advanced prostate cancer. However, after several years of ADT, most patients will ultimately progress to castration-resistant prostate cancer (CRPC). Previous studies mainly focus on Caucasian and very few on East Asian patients. METHODS: In this study, the pre- and post-ADT tumor samples were collected from five Chinese patients with advanced prostate cancer. The whole-exome sequencing, tumor heterogeneity, and clonal evolution pattern were analyzed. RESULTS: The results showed that the gene mutation pattern and heterogeneity changed significantly after androgen deprivation therapy. Tumor Mutational Burden (TMB) and Copy Number Alteration (CNA) were substantially reduced in the post-treatment group, but the Mutant-allele tumor heterogeneity (MATH), Socio-Demographic Index (SDI), Intratumor heterogeneity (ITH), and weighted Genome Instability Index (wGII) had no significant difference. According to the clone types and characteristics, the presence of main clones in five pre-and post-treatment samples, the clonal evolution pattern can be further classified into two sub-groups (the Homogeneous origin clonal model or the Heterogeneous origin clonal model). The Progression-free survival (PFS) of the patients with the “Homogeneous origin clonal model” was shorter than the “Heterogeneous origin clonal model”. The longer PFS might relate to MUC7 and MUC5B mutations repaired. ZNF91 mutation might be responsible for resistance to ADT resistance. CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04320-2. BioMed Central 2023-09-19 /pmc/articles/PMC10510184/ /pubmed/37726835 http://dx.doi.org/10.1186/s12967-023-04320-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Ao
Gao, Yi
Wang, Qi
Lin, Wenhao
Ma, Zhiyang
Yang, Xiaoqun
Chen, Lu
Xu, Danfeng
The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance
title The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance
title_full The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance
title_fullStr The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance
title_full_unstemmed The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance
title_short The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance
title_sort heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510184/
https://www.ncbi.nlm.nih.gov/pubmed/37726835
http://dx.doi.org/10.1186/s12967-023-04320-2
work_keys_str_mv AT liuao theheterogeneityandclonalevolutionanalysisoftheadvancedprostatecancerwithcastrationresistance
AT gaoyi theheterogeneityandclonalevolutionanalysisoftheadvancedprostatecancerwithcastrationresistance
AT wangqi theheterogeneityandclonalevolutionanalysisoftheadvancedprostatecancerwithcastrationresistance
AT linwenhao theheterogeneityandclonalevolutionanalysisoftheadvancedprostatecancerwithcastrationresistance
AT mazhiyang theheterogeneityandclonalevolutionanalysisoftheadvancedprostatecancerwithcastrationresistance
AT yangxiaoqun theheterogeneityandclonalevolutionanalysisoftheadvancedprostatecancerwithcastrationresistance
AT chenlu theheterogeneityandclonalevolutionanalysisoftheadvancedprostatecancerwithcastrationresistance
AT xudanfeng theheterogeneityandclonalevolutionanalysisoftheadvancedprostatecancerwithcastrationresistance
AT liuao heterogeneityandclonalevolutionanalysisoftheadvancedprostatecancerwithcastrationresistance
AT gaoyi heterogeneityandclonalevolutionanalysisoftheadvancedprostatecancerwithcastrationresistance
AT wangqi heterogeneityandclonalevolutionanalysisoftheadvancedprostatecancerwithcastrationresistance
AT linwenhao heterogeneityandclonalevolutionanalysisoftheadvancedprostatecancerwithcastrationresistance
AT mazhiyang heterogeneityandclonalevolutionanalysisoftheadvancedprostatecancerwithcastrationresistance
AT yangxiaoqun heterogeneityandclonalevolutionanalysisoftheadvancedprostatecancerwithcastrationresistance
AT chenlu heterogeneityandclonalevolutionanalysisoftheadvancedprostatecancerwithcastrationresistance
AT xudanfeng heterogeneityandclonalevolutionanalysisoftheadvancedprostatecancerwithcastrationresistance